Epizyme Appoints Chief Development Officer

Peter Ho, M.D., Ph.D., has been named chief development officer at Epizyme, Inc., and Michael Shih, J.D. has been named vice president, business development.
 
Dr. Ho will lead Epizyme’s clinical development, regulatory and translational medicine functions. He previously held positions with Johnson & Johnson, GlaxoSmithKline, DuPont Pharma and Novartis, and has successfully led teams and guided therapeutic development from Phase I through Phase III. Dr. Ho’s development experience includes Gleevec, Arranon, Tykerb, Votrient, and Promacta.
 
Mr. Shih will lead the company’s partnership strategy and execution. Most recently, he served as senior director of business development at Forest Laboratories, responsible for screening, sourcing and negotiating strategic partnership opportunities across several therapeutic areas. Prior to Forest, Mr. Shih was senior director of business development at Eisai, where his accomplishments included the EZH2 collaboration with Epizyme.
 
“We are very pleased to welcome Peter and Michael to Epizyme,” said Robert Gould, Ph.D., chief executive officer, Epizyme. “We expect Peter’s expertise in translational medicine and oncology clinical development and Michael’s experience in strategic partnerships on a global scale will be vital as we continue to execute on our strategy of building a fully integrated biopharmaceutical company.”